<DOC>
	<DOCNO>NCT01033760</DOCNO>
	<brief_summary>The purpose trial assess impact raltegravir , maraviroc , darunavir/r , Truvada® ( emtricitabine/tenofovir ) vs. darunavir/r Truvada® cell-associated HIV-DNA level patient primary HIV-1 infection .</brief_summary>
	<brief_title>Optimisation Primary HIV1 Infection Treatment ( ANRS 147 OPTIPRIM )</brief_title>
	<detailed_description>Primary HIV-1 infection characterize phase intense replication , quick dissemination early change immune system . During primary HIV-1 infection , damage MALT GALT promote chronic cell activation , participate progressive decay immune function . After HAART initiation , magnitude rapidity cell-associated HIV-DNA decrease significantly high patient primary HIV-1 infection patient chronic infection ( Ngo Giang Huong , AIDS 2004 ) . We hypothesize early intervention different level viral replication potent well-tolerated new drug may great impact cell-associated HIV-DNA level conventional triple-drug HAART .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Patients acute primary HIV1 infection Acute infection : negative slightly positive Elisa , negative incomplete westernblot ( 0 1 antibody ) positive HIVRNA and/or positive Ag p24 . Primary infection : positive Elisa incomplete Westernblot ( ≥ 2 &lt; 5 antibody presence antip24 antibody associate antigp160 antigp120 antigp41antibody ) positive HIVRNA . Symptomatic Primary infection CD4 &lt; 500/mm3 write informed consent ≥ 18 year old Prior post exposure antiretroviral treatment within six month enrolment Pregnancy breastfeed HIV2 infection Current malignancy Prothrombin time &lt; 50 % Creatinine clearance &lt; 60 ml/min ASAT , ALAT bilirubin ≥10*N Platelets &lt; 25000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Primary HIV-1 infection</keyword>
	<keyword>antiretroviral treatment</keyword>
	<keyword>HIV reservoir</keyword>
	<keyword>HIV-DNA level</keyword>
	<keyword>randomize</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>